Pricing Sign in

BEAM

Beam Therapeutics Inc.distress 0/10 · well-funded / low risk

$25.78-3%today-32% from 52w high

beamtx.com522 employeesFounded 2017Cambridge, MABiotechnology

Lead: Alpha-1 Antitrypsin Deficiency (AATD)

Revenue

$32M

Liquidity

$1236M

Runway

3.3 yrs

Shares 1y

+2%

Price & events

-24.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.2%

1D

-9.2%

1W

-22.3%

1M

-14.5%

3M

-18.3%

6M

+16.3%

1Y

-15.0%

2Y

-72.1%

5Y

-69.0%

All

Overview

Market Cap: $2.65B
Enterprise Value: $2.46B
Volume: 220.87K
52 Week Range: $16.01 – $37.92
Total Shares: 102.88M
Float Shares: 87.94M
Short %: 34.46%
% Held by Insiders: 1.40%
% Held by Institutions: 106.85%
RVOL: 0.09x
Beta: 2.18

Pipeline stages · 1 programs

BEAM-302

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-12

Pipeline · 5 trials · 4 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-12 Estimated 50% readout ~2027-01-15	Phase 1/2	BEAM-201	Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia	—	active not recruiting
2027-12-30 Estimated 50% readout ~2028-02-13	Phase 1/2	BEAM-301: Single dose of BEAM-301 administered by IV	Glycogen Storage Disease Type Ia	—	recruiting
2028-02 Estimated 50% readout ~2028-03-17	Phase 1/2	BEAM-101	Sickle Cell Disease	—	active not recruiting
2028-05 Estimated 50% readout ~2028-06-15	Phase 1/2	BEAM-302	Alpha 1-Antitrypsin Deficiency	—	recruiting
2026-01-29	Phase 1	BEAM-103	Healthy Subjects, Healthy Participant Study	30	recruiting

Catalyst news & presentations · 11

2026Guided 40%conferencedata presentationsecondaryBEAM-302 · Presentation of topline clinical data at the ATS 2026 International Conference.PR wire
Year-End 2026Guided 40%regulatory submissionFiled (NDA/BLA)risto-cel · BLA submission expected as early as year-end 2026.SEC 8-K
2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
EHA2026conferencedata presentationsecondaryRisto-cel · Present updated biomarker data from Phase 1/2 BEACON trial.PR wire
January 13, 2026conferencedata presentationsecondaryInvestor presentation at the 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
2026-01-11fda agreementBEAM-302 · Alignment reached with U.S. FDA on potential accelerated approval pathway for AATD based on biomarker endpoints.SEC 8-K
second half of 2025conferencedata presentationsecondaryPhase 1/2BEAM-302 · Further clinical data presentation at a medical conferenceSEC 8-K
second half of 2025trial initiationsecondaryPhase 1/2BEAM-302 · Initiation of Part B dose escalation for patients with mild to moderate liver diseaseSEC 8-K
first half of 2025readoutPhase 1/2BEAM-302 · Initial clinical data from multiple cohorts.SEC 8-K
Monday, Dec. 9, 6-8 p.m. PTconferencedata presentationsecondaryPhase 1/2BEAM-201 · Poster presentation of initial data from Phase 1/2 studySEC 8-K
Sunday, Dec. 8, 10:45 a.m. PTconferencedata presentationsecondaryESCAPE · Preclinical data for ESCAPE in rhesus autologous transplantation modelSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 102,879,214 · 0 offerings/1y · 0 PIPEs

2026-02-248-Kmaterial_agreement
2026-02-128-Kmaterial_agreement
2025-07-038-Kprivate_placement
2025-03-108-Kmaterial_agreement
2025-03-10424B5offering
2025-03-10FWPoffering
2025-03-10424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $52 (+103% upside) · 13 analysts

2026-07-08B of A SecuritiesBuy
2026-07-07HC Wainwright & Co.Buy
2026-05-13BernsteinOutperform
2026-03-26CitigroupBuy
2026-02-25RBC CapitalSector Perform
2026-02-25WedbushOutperform

Competitors — Alpha-1 Antitrypsin Deficiency (AATD)

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.